Note B - The Company and its Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Mar. 24, 2025	Mar. 07, 2025	Nov. 27, 2023
Net loss		$ (2,055,000)	$ (816,000)
Retained Earnings (Accumulated Deficit)		(4,445,000)	(2,390,000)
Cash and Cash Equivalents, at Carrying Value		4,034,000	466,000
Working Capital (Deficit)		$ 3,917,000	$ (80,000)
Common Stock, Shares, Outstanding (in shares)		19,984,924	9,284,924			9,284,924
Revenue from Contract with Customer, Excluding Assessed Tax		$ 0	$ 0
Equity Method Investments		0	189,000
Goodwill		0
Unrecognized Tax Benefits		$ 0	$ 0
Weighted Average Number of Shares Outstanding, Diluted, Adjustment		0	0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		0	0
Advertising Expense		$ 0	$ 0
Domestic Tax Jurisdiction [Member]
Open Tax Year		2019 2020 2021 2022 2023 2024
State and Local Jurisdiction [Member]
Open Tax Year		2019 2020 2021 2022 2023 2024
Medical Oncology Partners [Member]
Equity Method Investments		$ 0
CB Oncology Partners ("CBOP") [Member]
Equity Method Investments		0
NYU Agreement [Member]
Accounts Receivable, after Allowance for Credit Loss		$ 0	$ 0
Subsequent Event [Member]
Proceeds from Issuance of Private Placement	$ 5,825,000
Stock Issued During Period, Shares, New Issues	11,650,000
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture	475,000
Common Stock, Shares, Outstanding (in shares)	21,409,924			21,409,924	21,409,924